{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:28:00Z","timestamp":1786548480374,"version":"build-2736575974"},"reference-count":148,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35GM137901"],"award-info":[{"award-number":["R35GM137901"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["R01EB031830"],"award-info":[{"award-number":["R01EB031830"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA276240"],"award-info":[{"award-number":["R01CA276240"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Precise control over how and where small-molecule drugs are covalently attached to monoclonal antibodies is increasingly vital for creating consistently efficacious and safe antibody\u2013drug conjugates (ADCs) as powerful targeted therapies. Enzymatic conjugation methods have gained considerable attention for their abilities to efficiently install payloads at defined locations under mild and predictable conditions. This work provides a comprehensive review of current enzymatic technologies for site-specific ADC construction, organized by the biological origin of enzymes. Among various enzyme-based conjugating approaches, a special focus is given to the emerging ADP-ribosyl cyclase\u2013enabled ADC (ARC-ADC) platform. By utilizing genetically fused CD38, a member of the ARC family, together with its dinucleotide-derived inhibitor, site-specific ADCs with defined drug-to-antibody ratios in varied formats could be facilely produced with demonstrated efficacy and specificity in preclinical models of different types of cancer. Unlike most enzymatic methods requiring recognition tags or external catalytic steps, ARC-ADC provides a fully integrated, modular strategy for streamlined ADC discovery and development.<\/jats:p>","DOI":"10.1093\/abt\/tbag020","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T13:22:33Z","timestamp":1777468953000},"page":"259-272","source":"Crossref","is-referenced-by-count":0,"title":["The evolving landscape of enzymatic technologies for precision synthesis of antibody\u2013drug conjugates"],"prefix":"10.1093","volume":"9","author":[{"given":"Thuc Oanh","family":"Hoang","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California , Los Angeles, CA 90089 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad J","family":"Ansari","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California , Los Angeles, CA 90089 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3132-8557","authenticated-orcid":false,"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California , Los Angeles, CA 90089 ,","place":["United States"]},{"name":"Department of Chemistry, Dornsife College of Letters, Arts and Sciences, University of Southern California , Los Angeles, CA 90089 ,","place":["United States"]},{"name":"Norris Comprehensive Cancer Center, University of Southern California , Los Angeles, CA 90089 ,","place":["United States"]},{"name":"Research Center for Liver Diseases, University of Southern California , Los Angeles, CA 90089 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"2026081210261859800_ref1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/bmj.2.2746.353","article-title":"Address in pathology, on chemiotherapy: delivered before the Seventeenth International Congress of Medicine","volume":"2","author":"Ehrlich","year":"1913","journal-title":"Br Med J"},{"key":"2026081210261859800_ref2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"2026081210261859800_ref3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"2026081210261859800_ref4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J Hematol Oncol"},{"key":"2026081210261859800_ref5","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1186\/s12885-024-12652-5","article-title":"Landscape of clinical drug development of ADCs used for the pharmacotherapy of cancers: an overview of clinical trial registry data from 2002 to 2022","volume":"24","author":"Zhou","year":"2024","journal-title":"BMC Cancer"},{"key":"2026081210261859800_ref6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.taap.2013.09.003","article-title":"Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability","volume":"273","author":"Poon","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"2026081210261859800_ref7","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat Biotechnol"},{"key":"2026081210261859800_ref8","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","article-title":"The therapeutic window of antibody drug conjugates: a dogma in need of revision","volume":"40","author":"Colombo","year":"2022","journal-title":"Cancer Cell"},{"key":"2026081210261859800_ref9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1158\/0008-5472.CAN-22-1433","article-title":"Immunotherapeutic targeting and PET imaging of DLL3 in small-cell neuroendocrine prostate cancer","volume":"83","author":"Chou","year":"2023","journal-title":"Cancer Res"},{"key":"2026081210261859800_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217535","article-title":"How to design next-generation of antibody-drug conjugates for cancer treatment: lessons from unsuccessful clinical trials","volume":"623","author":"Jian","year":"2025","journal-title":"Cancer Lett"},{"key":"2026081210261859800_ref11","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s10637-017-0473-9","article-title":"A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C","volume":"35","author":"Almhanna","year":"2017","journal-title":"Invest New Drugs"},{"key":"2026081210261859800_ref12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers"},{"key":"2026081210261859800_ref13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-025-01212-0","article-title":"The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development","volume":"15","author":"Mukhopadhyay","year":"2025","journal-title":"Blood Cancer J"},{"key":"2026081210261859800_ref14","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"2026081210261859800_ref15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s10875-016-0265-6","article-title":"Current status: site-specific antibody drug conjugates","volume":"36","author":"Schumacher","year":"2016","journal-title":"J Clin Immunol"},{"key":"2026081210261859800_ref16","doi-asserted-by":"publisher","first-page":"9303","DOI":"10.1039\/D0SC01795G","article-title":"A poly-ADP-ribose polymer-based antibody-drug conjugate","volume":"11","author":"Shi","year":"2020","journal-title":"Chem Sci"},{"key":"2026081210261859800_ref17","first-page":"37","volume-title":"Antibody-Drug Conjugates: Methods and Protocols","author":"Nadkarni","year":"2019"},{"key":"2026081210261859800_ref18","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/pro.3913","article-title":"A humanized antibody inhibitor for cathepsin L","volume":"29","author":"Shi","year":"2020","journal-title":"Protein Sci"},{"key":"2026081210261859800_ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2023.109849","article-title":"Rational design of humanized antibody inhibitors for cathepsin S","volume":"751","author":"Yu","year":"2023","journal-title":"Arch Biochem Biophys"},{"key":"2026081210261859800_ref20","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1039\/D0CS00310G","article-title":"Site-selective modification strategies in antibody-drug conjugates","volume":"50","author":"Walsh","year":"2021","journal-title":"Chem Soc Rev"},{"key":"2026081210261859800_ref21","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/abt\/tbaa027","article-title":"Site-specific conjugation of native antibody","volume":"3","author":"Sadiki","year":"2020","journal-title":"Antib Ther"},{"key":"2026081210261859800_ref22","doi-asserted-by":"publisher","first-page":"9107","DOI":"10.7150\/thno.62444","article-title":"Synthesis of precision antibody conjugates using proximity-induced chemistry","volume":"11","author":"Cao","year":"2021","journal-title":"Theranostics"},{"key":"2026081210261859800_ref23","doi-asserted-by":"publisher","first-page":"5648","DOI":"10.1002\/ange.201814215","article-title":"AJICAP: affinity peptide mediated regiodivergent functionalization of native antibodies","volume":"131","author":"Yamada","year":"2019","journal-title":"Angewandte Chemie"},{"key":"2026081210261859800_ref24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/antib7010004","article-title":"Enzyme-based labeling strategies for antibody\u2013drug conjugates and antibody mimetics","volume":"7","author":"Falck","year":"2018","journal-title":"Antibodies"},{"key":"2026081210261859800_ref25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/ph14040343","article-title":"Toward homogenous antibody drug conjugates using enzyme-based conjugation approaches","volume":"14","author":"Hussain","year":"2021","journal-title":"Pharmaceuticals"},{"key":"2026081210261859800_ref26","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1021\/acs.oprd.3c00111","article-title":"Scale-up synthesis of site-specific antibody\u2013drug conjugates using AJICAP second-generation technology","volume":"27","author":"Watanabe","year":"2023","journal-title":"Org Process Res Dev"},{"key":"2026081210261859800_ref27","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41551-019-0470-8","article-title":"Computationally designed antibody-drug conjugates self-assembled via affinity ligands","volume":"3","author":"Gupta","year":"2019","journal-title":"Nat Biomed Eng"},{"key":"2026081210261859800_ref28","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1021\/acs.bioconjchem.0c00061","article-title":"Site-specific conjugation of native antibodies using engineered microbial transglutaminases","volume":"31","author":"Dickgiesser","year":"2020","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref29","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1021\/bc400574z","article-title":"Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody\u2013drug conjugates","volume":"25","author":"Dennler","year":"2014","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41420-024-01845-3","article-title":"Antibody and antibody fragments site-specific conjugation using new Q-tag substrate of bacterial transglutaminase","volume":"10","author":"El Alaoui","year":"2024","journal-title":"Cell Death Discov"},{"key":"2026081210261859800_ref31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41698-024-00687-7","article-title":"First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors","volume":"8","author":"Zhang","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2026081210261859800_ref32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1039\/D4MD00637B","article-title":"Technical, preclinical, and clinical developments of Fc-glycan-specific antibody\u2013drug conjugates","volume":"16","author":"Yang","year":"2025","journal-title":"RSC Med Chem"},{"key":"2026081210261859800_ref33","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1021\/acs.bioconjchem.4c00013","article-title":"Site-specific conjugation of native antibody: transglutaminase-mediated modification of a conserved glutamine while maintaining the primary sequence and core Fc glycan via trimming with an endoglycosidase","volume":"35","author":"Sadiki","year":"2024","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/antib12040071","article-title":"Evaluation of two chemoenzymatic glycan remodeling approaches to generate site-specific antibody\u2013drug conjugates","volume":"12","author":"Yang","year":"2023","journal-title":"Antibodies"},{"key":"2026081210261859800_ref35","volume-title":"Antibody-Pyrrolobenzodiazepine Derivative Conjugate","author":"Toda","year":"2022"},{"key":"2026081210261859800_ref36","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1021\/acs.bioconjchem.1c00246","article-title":"Site-specific conjugation strategy for dual antibody\u2013drug conjugates using aerobic formylglycine-generating enzymes","volume":"32","author":"Boschanski","year":"2021","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref37","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1073\/pnas.0807820106","article-title":"Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag","volume":"106","author":"Wu","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"2026081210261859800_ref38","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.3390\/ijms23052468","article-title":"Bivalent EGFR-targeting DARPin-MMAE conjugates","volume":"23","author":"Karsten","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026081210261859800_ref39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-9546-2_1","volume-title":"Enzyme-Mediated Ligation Methods","author":"G\u00e9bleux","year":"2019"},{"key":"2026081210261859800_ref40","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1158\/1535-7163.MCT-16-0688","article-title":"Highly potent, anthracycline-based antibody\u2013drug conjugates generated by enzymatic, site-specific conjugation","volume":"16","author":"Stefan","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2026081210261859800_ref41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131177","article-title":"Sortase enzyme-mediated generation of site-specifically conjugated antibody drug conjugates with high in vitro and in vivo potency","volume":"10","author":"Beerli","year":"2015","journal-title":"PloS One"},{"key":"2026081210261859800_ref42","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.biomaterials.2018.06.017","article-title":"Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1","volume":"178","author":"Lai","year":"2018","journal-title":"Biomaterials"},{"key":"2026081210261859800_ref43","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201602267","article-title":"Sortase A-generated highly potent anti-CD20-MMAE conjugates for efficient elimination of B-lineage lymphomas","volume":"13","author":"Pan","year":"2017","journal-title":"Small"},{"key":"2026081210261859800_ref44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejps.2019.04.015","article-title":"High antitumor activity of Sortase A-generated anti-CD20 antibody fragment drug conjugates","volume":"134","author":"Liu","year":"2019","journal-title":"Eur J Pharm Sci"},{"key":"2026081210261859800_ref45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1108","article-title":"NBE-002: a novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors\u2014a phase 1\/2 clinical trial","volume":"39","author":"Tolcher","year":"2021","journal-title":"Wolters Kluwer Health"},{"key":"2026081210261859800_ref46","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1021\/acs.bioconjchem.5b00558","article-title":"Efficient preparation of site-specific antibody\u2013drug conjugates using phosphopantetheinyl transferases","volume":"26","author":"Grunewald","year":"2015","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref47","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1021\/acs.bioconjchem.7b00236","article-title":"Optimization of an enzymatic antibody\u2013drug conjugation approach based on coenzyme A analogs","volume":"28","author":"Grunewald","year":"2017","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref48","doi-asserted-by":"publisher","DOI":"10.1002\/cbdv.202402113","article-title":"Antibody modification via lipoic acid ligase A-mediated site-specific Labeling","volume":"22","author":"Yamazaki","year":"2025","journal-title":"Chem Biodivers"},{"key":"2026081210261859800_ref49","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1021\/acs.biochem.3c00513","article-title":"Biological evaluation of antibody-drug conjugates produced by tag-free lipoate ligase A modification","volume":"63","author":"Yamazaki","year":"2024","journal-title":"Biochemistry"},{"key":"2026081210261859800_ref50","doi-asserted-by":"publisher","first-page":"16091","DOI":"10.1016\/S0021-9258(17)33977-7","article-title":"Identification of the gene encoding lipoate-protein ligase A of Escherichia coli. Molecular cloning and characterization of the lplA gene and gene product","volume":"269","author":"Morris","year":"1994","journal-title":"J Biol Chem"},{"key":"2026081210261859800_ref51","doi-asserted-by":"publisher","DOI":"10.1002\/cbic.202500261","article-title":"A recognition tag of human origin for bioorthogonal generation of antibody-drug conjugates using microbial biotin ligase","volume":"26","author":"Bitsch","year":"2025","journal-title":"ChemBioChem"},{"key":"2026081210261859800_ref52","doi-asserted-by":"publisher","first-page":"7782","DOI":"10.1039\/D3SC02543H","article-title":"Recent developments in the cleavage, functionalization, and conjugation of proteins and peptides at tyrosine residues","volume":"14","author":"Zhang","year":"2023","journal-title":"Chem Sci"},{"key":"2026081210261859800_ref53","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1021\/acs.bioconjchem.2c00576","article-title":"Modification of cysteine-substituted antibodies using enzymatic oxidative coupling reactions","volume":"34","author":"Cao","year":"2023","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref54","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1021\/acs.bioconjchem.8b00563","article-title":"One-pot dual labeling of IgG 1 and preparation of C-to-C fusion proteins through a combination of sortase A and butelase 1","volume":"29","author":"Harmand","year":"2018","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref55","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s11426-019-9648-3","article-title":"Peptide asparaginyl ligases\u2014renegade peptide bond makers","volume":"63","author":"Tam","year":"2020","journal-title":"Sci China Chem"},{"key":"2026081210261859800_ref56","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3390\/ijms23010458","article-title":"Vypal2: a versatile peptide ligase for precision tailoring of proteins","volume":"23","author":"Zhang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026081210261859800_ref57","volume-title":"Antibody-Active Agent Conjugates and Methods of Use","author":"Kim","year":"2017"},{"key":"2026081210261859800_ref58","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.3390\/molecules25071515","article-title":"Quantification of an antibody-conjugated drug in fat plasma by an affinity capture LC-MS\/MS method for a novel prenyl transferase-mediated site-specific antibody\u2013drug conjugate","volume":"25","author":"Lee","year":"2020","journal-title":"Molecules"},{"key":"2026081210261859800_ref59","doi-asserted-by":"publisher","first-page":"5158","DOI":"10.1038\/s41467-024-48798-w","article-title":"HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a\/1b trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"2026081210261859800_ref60","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1021\/bc400505q","article-title":"Site-specific antibody\u2013drug conjugation through glycoengineering","volume":"25","author":"Zhou","year":"2014","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref61","doi-asserted-by":"publisher","first-page":"7307","DOI":"10.1002\/ange.201402606","article-title":"Preparation of well-defined antibody\u2013drug conjugates through glycan remodeling and strain-promoted azide\u2013alkyne cycloadditions","volume":"126","author":"Li","year":"2014","journal-title":"Angewandte Chemie"},{"key":"2026081210261859800_ref62","doi-asserted-by":"publisher","volume-title":"MAbs","author":"Wijdeven","DOI":"10.1080\/19420862.2022.2078466"},{"key":"2026081210261859800_ref63","doi-asserted-by":"publisher","first-page":"13787","DOI":"10.1002\/anie.201505456","article-title":"Versatile and efficient site-specific protein functionalization by tubulin tyrosine ligase","volume":"54","author":"Schumacher","year":"2015","journal-title":"Angew Chem Int Ed"},{"key":"2026081210261859800_ref64","doi-asserted-by":"publisher","article-title":"TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacy","author":"Gerlach","DOI":"10.1158\/1535-7163.mct-25-0062"},{"key":"2026081210261859800_ref65","doi-asserted-by":"publisher","first-page":"18888","DOI":"10.1021\/jacs.5c02981","article-title":"Orthogonal site-specific dual bioconjugation of aryl and alkyl thiols","volume":"147","author":"Geus","year":"2025","journal-title":"J Am Chem Soc"},{"key":"2026081210261859800_ref66","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba6752","article-title":"Synthesis of site-specific antibody-drug conjugates by ADP-ribosyl cyclases","volume":"6","author":"Dai","year":"2020","journal-title":"Sci Adv"},{"key":"2026081210261859800_ref67","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118274","article-title":"Targeting prostate cancer with site-specific antibody-drug conjugates enabled by tandemly fused ADP-ribosyl cyclases","volume":"189","author":"Zhang","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"2026081210261859800_ref68","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jconrel.2021.06.041","article-title":"Site-specific antibody-drug conjugates with variable drug-to-antibody-ratios for AML therapy","volume":"336","author":"Dai","year":"2021","journal-title":"J Control Release"},{"key":"2026081210261859800_ref69","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4924","article-title":"Synthesis of site-specific Fab-drug conjugates using ADP-ribosyl cyclases","volume":"33","author":"Kim","year":"2024","journal-title":"Protein Sci"},{"key":"2026081210261859800_ref70","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1038\/s41596-019-0214-y","article-title":"One-step site-specific antibody fragment auto-conjugation using SNAP-tag technology","volume":"14","author":"Hussain","year":"2019","journal-title":"Nat Protoc"},{"key":"2026081210261859800_ref71","doi-asserted-by":"publisher","first-page":"12203","DOI":"10.1007\/s00432-023-05031-3","article-title":"CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate","volume":"149","author":"Mungra","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026081210261859800_ref72","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1021\/acsomega.2c06844","article-title":"Click chemistry-generated auristatin F\u2013linker\u2013benzylguanine for a SNAP-tag-based recombinant antibody\u2013drug conjugate demonstrating selective cytotoxicity toward EGFR-overexpressing tumor cells","volume":"8","author":"Huysamen","year":"2023","journal-title":"ACS Omega"},{"key":"2026081210261859800_ref73","doi-asserted-by":"publisher","DOI":"10.1038\/srep39291","article-title":"Spontaneous isopeptide bond formation as a powerful tool for engineering site-specific antibody-drug conjugates","volume":"6","author":"Siegmund","year":"2016","journal-title":"Sci Rep"},{"key":"2026081210261859800_ref74","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s11307-018-1222-y","article-title":"Site-specific fluorescent labeling of antibodies and diabodies using SpyTag\/SpyCatcher system for in vivo optical imaging","volume":"21","author":"Alam","year":"2019","journal-title":"Mol Imaging Biol"},{"key":"2026081210261859800_ref75","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1021\/acs.bioconjchem.8b00630","article-title":"Site-specific antibody drug conjugates using streamlined expressed protein ligation","volume":"29","author":"Frutos","year":"2018","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref76","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1002\/anie.201307736","article-title":"N-terminal protein modification by substrate-activated reverse proteolysis","volume":"53","author":"Liebscher","year":"2014","journal-title":"Angew Chem Int Ed"},{"key":"2026081210261859800_ref77","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1021\/acs.bioconjchem.5b00618","article-title":"Selective coupling of click anchors to proteins via trypsiligase","volume":"27","author":"Meyer","year":"2016","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref78","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/cbic.201400059","article-title":"Derivatization of antibody Fab fragments: a designer enzyme for native protein modification","volume":"15","author":"Liebscher","year":"2014","journal-title":"ChemBioChem"},{"key":"2026081210261859800_ref79","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/978-1-4939-9546-2_8","volume-title":"Enzyme-Mediated Ligation Methods","author":"Dickgiesser","year":"2019"},{"key":"2026081210261859800_ref80","doi-asserted-by":"publisher","first-page":"33510","DOI":"10.1039\/D2RA05630E","article-title":"Tag-free, specific conjugation of glycosylated IgG1 antibodies using microbial transglutaminase","volume":"12","author":"Hadjabdelhafid-Parisien","year":"2022","journal-title":"RSC Adv"},{"key":"2026081210261859800_ref81","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1016\/j.xphs.2023.08.006","article-title":"Investigation of high molecular weight size variant formation in antibody-drug conjugates: microbial transglutaminase-mediated crosslinking","volume":"112","author":"Zhao","year":"2023","journal-title":"J Pharm Sci"},{"key":"2026081210261859800_ref82","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1021\/ja510519u","article-title":"Rational design of humanized dual-agonist antibodies","volume":"137","author":"Zhang","year":"2015","journal-title":"J Am Chem Soc"},{"key":"2026081210261859800_ref83","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3390\/pharmaceutics17091164","article-title":"Strategic and chemical advances in antibody\u2013drug conjugates","volume":"17","author":"Alradwan","year":"2025","journal-title":"Pharmaceutics"},{"key":"2026081210261859800_ref84","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1002\/anie.201410049","article-title":"Rational design of a humanized glucagon-like peptide-1 receptor agonist antibody","volume":"54","author":"Zhang","year":"2015","journal-title":"Angew Chem Int Ed Engl"},{"key":"2026081210261859800_ref85","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1021\/acs.biochem.0c00046","article-title":"Rational design of a humanized antibody inhibitor of cathepsin B","volume":"59","author":"Dai","year":"2020","journal-title":"Biochemistry"},{"key":"2026081210261859800_ref86","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1021\/acs.biochem.2c00718","article-title":"Synthesis of bispecific antibody conjugates using functionalized poly-ADP-ribose polymers","volume":"62","author":"Cheng","year":"2023","journal-title":"Biochemistry"},{"key":"2026081210261859800_ref87","doi-asserted-by":"publisher","first-page":"16508","DOI":"10.1074\/jbc.M116.738765","article-title":"Glycosynthase mutants of endoglycosidase S2 show potent transglycosylation activity and remarkably relaxed substrate specificity for antibody glycosylation remodeling","volume":"291","author":"Li","year":"2016","journal-title":"J Biol Chem"},{"key":"2026081210261859800_ref88","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1021\/acschembio.1c00597","article-title":"General and robust chemoenzymatic method for glycan-mediated site-specific labeling and conjugation of antibodies: facile synthesis of homogeneous antibody\u2013drug conjugates","volume":"16","author":"Zhang","year":"2021","journal-title":"ACS Chem Biol"},{"key":"2026081210261859800_ref89","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1021\/acs.bioconjchem.5b00224","article-title":"Chemoenzymatic conjugation of toxic payloads to the globally conserved N-glycan of native mAbs provides homogeneous and highly efficacious antibody\u2013drug conjugates","volume":"26","author":"Van Geel","year":"2015","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref90","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1021\/cb500897w","article-title":"Formylglycine, a post-translationally generated residue with unique catalytic capabilities and biotechnology applications","volume":"10","author":"Appel","year":"2015","journal-title":"ACS Chem Biol"},{"key":"2026081210261859800_ref91","doi-asserted-by":"publisher","first-page":"12240","DOI":"10.1021\/ja804530w","article-title":"New aldehyde tag sequences identified by screening formylglycine generating enzymes in vitro and in vivo","volume":"130","author":"Rush","year":"2008","journal-title":"J Am Chem Soc"},{"key":"2026081210261859800_ref92","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ymeth.2019.09.017","article-title":"Reprogramming extracellular vesicles with engineered proteins","volume":"177","author":"Shi","year":"2020","journal-title":"Methods"},{"key":"2026081210261859800_ref93","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.114425","article-title":"Preclinical assessment of genetically modified exosomes for colorectal cancer immunotherapy","volume":"389","author":"Hoang","year":"2026","journal-title":"J Control Release"},{"key":"2026081210261859800_ref94","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1097\/01.HS9.0000847476.69621.cd","article-title":"P1152: results from a phase I pharmacokinetic (PK) and safety study of TRPH-222, a novel CD22-targeting antibody-drug conjugate, in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma (R\/R NHL)","volume":"6","author":"Hernandez-Ilizaliturri","year":"2022","journal-title":"HemaSphere"},{"key":"2026081210261859800_ref95","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/j.1365-2958.2011.07887.x","article-title":"Sortase enzymes in Gram-positive bacteria","volume":"82","author":"Spirig","year":"2011","journal-title":"Mol Microbiol"},{"key":"2026081210261859800_ref96","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.3390\/ijms18112284","article-title":"A versatile chemo-enzymatic conjugation approach yields homogeneous and highly potent antibody-drug conjugates","volume":"18","author":"Xu","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2026081210261859800_ref97","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1021\/acs.bioconjchem.1c00099","article-title":"Efficient labeling of native human IgG by proximity-based sortase-mediated isopeptide ligation","volume":"32","author":"Yu","year":"2021","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref98","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1182\/bloodadvances.2020003276","article-title":"The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia","volume":"5","author":"Hu","year":"2021","journal-title":"Blood Adv"},{"key":"2026081210261859800_ref99","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1021\/cb700054k","article-title":"Genetically encoded short peptide tags for orthogonal protein labeling by Sfp and AcpS phosphopantetheinyl transferases","volume":"2","author":"Zhou","year":"2007","journal-title":"ACS Chem Biol"},{"key":"2026081210261859800_ref100","doi-asserted-by":"publisher","first-page":"15815","DOI":"10.1073\/pnas.0507705102","article-title":"Genetically encoded short peptide tag for versatile protein labeling by Sfp phosphopantetheinyl transferase","volume":"102","author":"Yin","year":"2005","journal-title":"Proc Natl Acad Sci"},{"key":"2026081210261859800_ref101","doi-asserted-by":"publisher","first-page":"10914","DOI":"10.1073\/pnas.0914067107","article-title":"A fluorophore ligase for site-specific protein labeling inside living cells","volume":"107","author":"Uttamapinant","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"2026081210261859800_ref102","doi-asserted-by":"publisher","DOI":"10.1002\/slct.202204706","article-title":"Tag-free antibody modification mediated by lipoic acid ligase A: application to antibody-drug conjugates production","volume":"8","author":"Yamazaki","year":"2023","journal-title":"ChemistrySelect"},{"key":"2026081210261859800_ref103","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1021\/acs.bioconjchem.9b00244","article-title":"Dual site-specific antibody conjugates for sequential and orthogonal cargo release","volume":"30","author":"Thornlow","year":"2019","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref104","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1021\/ja076655i","article-title":"Expanding the substrate tolerance of biotin ligase through exploration of enzymes from diverse species","volume":"130","author":"Slavoff","year":"2008","journal-title":"J Am Chem Soc"},{"key":"2026081210261859800_ref105","doi-asserted-by":"publisher","first-page":"e2417260","DOI":"10.1002\/advs.202417260","article-title":"Bioorthogonal reaction of o-quinone with furan-2 (3H)-one for site-selective tyrosine conjugation and construction of bispecific antibody complexes","volume":"12","author":"Chen","year":"2025","journal-title":"Adv Sci"},{"key":"2026081210261859800_ref106","doi-asserted-by":"publisher","first-page":"5863","DOI":"10.7150\/thno.53615","article-title":"Engineering protein theranostics using bio-orthogonal asparaginyl peptide ligases","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"2026081210261859800_ref107","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00775-004-0612-6","article-title":"Unraveling the mechanism of the farnesyltransferase enzyme","volume":"10","author":"Sousa","year":"2005","journal-title":"JBIC"},{"key":"2026081210261859800_ref108","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/978-1-4939-9654-4_14","volume-title":"Bioconjugation: Methods and Protocols","author":"Zhang","year":"2019"},{"key":"2026081210261859800_ref109","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1042\/BST20253076","article-title":"Engineering protein prenylation: an emerging tool for selective protein modification","volume":"53","author":"Venkatachalapathy","year":"2025","journal-title":"Biochem Soc Trans"},{"key":"2026081210261859800_ref110","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/abt\/tbaf010","article-title":"A review of conjugation technologies for antibody drug conjugates","volume":"8","author":"Fan","year":"2025","journal-title":"Antib Ther"},{"key":"2026081210261859800_ref111","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1021\/bc900103p","article-title":"Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection","volume":"20","author":"Boeggeman","year":"2009","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref112","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1021\/acs.bioconjchem.3c00302","article-title":"Site-specific antibody conjugation using modified bisected N-glycans: method development and potential toward tunable effector function","volume":"34","author":"Hsu","year":"2023","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref113","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/bies.950130605","article-title":"Stabilization and post-translational modification of microtubules during cellular morphogenesis","volume":"13","author":"Bulinski","year":"1991","journal-title":"Bioessays"},{"key":"2026081210261859800_ref114","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.copbio.2005.06.001","article-title":"Adding value to fusion proteins through covalent labelling","volume":"16","author":"Gronemeyer","year":"2005","journal-title":"Curr Opin Biotechnol"},{"key":"2026081210261859800_ref115","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.canlet.2016.08.003","article-title":"The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F","volume":"381","author":"Woitok","year":"2016","journal-title":"Cancer Lett"},{"key":"2026081210261859800_ref116","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1021\/acs.bioconjchem.5b00191","article-title":"HaloTag technology: a versatile platform for biomedical applications","volume":"26","author":"England","year":"2015","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref117","doi-asserted-by":"publisher","first-page":"E1176","DOI":"10.1073\/pnas.1315776111","article-title":"SpyLigase peptide\u2013peptide ligation polymerizes affibodies to enhance magnetic cancer cell capture","volume":"111","author":"Fierer","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"2026081210261859800_ref118","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115385","article-title":"Site-directed immobilization of Pseudomonas fluorescens lipase based on SnoopCatcher\/SnoopTag system for biodiesel production","volume":"26","author":"Zhang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026081210261859800_ref119","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1021\/jacs.7b13237","article-title":"SnoopLigase catalyzes peptide-peptide locking and enables solid-phase conjugate isolation","volume":"140","author":"Buldun","year":"2018","journal-title":"J Am Chem Soc"},{"key":"2026081210261859800_ref120","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1472-6750-11-76","article-title":"Site-specific modification of ED-B-targeting antibody using intein-fusion technology","volume":"11","author":"M\u00f6hlmann","year":"2011","journal-title":"BMC Biotechnol"},{"key":"2026081210261859800_ref121","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.1021\/jacsau.4c00695","article-title":"Nicotinamide riboside and CD38: covalent inhibition and live-cell labeling","volume":"4","author":"Kao","year":"2024","journal-title":"JACS Au"},{"key":"2026081210261859800_ref122","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/s41467-025-67661-0","article-title":"A versatile platform for chemical engineering of exosomes empowered by ADP-ribosyl cyclases","volume":"17","author":"Zhang","year":"2026","journal-title":"Nat Commun"},{"key":"2026081210261859800_ref123","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2119\/2006-00086.Lee","article-title":"Structure and enzymatic functions of human CD38","volume":"12","author":"Lee","year":"2006","journal-title":"Mol Med"},{"key":"2026081210261859800_ref124","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202518329","article-title":"Synthesis of bispecific conjugates by ADP-ribosyl cyclases","volume":"13","author":"Kim","year":"2026","journal-title":"Adv Sci (Weinh)"},{"key":"2026081210261859800_ref125","doi-asserted-by":"publisher","first-page":"C521","DOI":"10.1152\/ajpcell.00451.2021","article-title":"The CD38 glycohydrolase and the NAD sink: implications for pathological conditions","volume":"322","author":"Zeidler","year":"2022","journal-title":"Am J Physiol Cell Physiol"},{"key":"2026081210261859800_ref126","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ab.2017.12.019","article-title":"A macrodomain-linked immunosorbent assay (MLISA) for mono-ADP-ribosyltransferases","volume":"543","author":"Chen","year":"2018","journal-title":"Anal Biochem"},{"key":"2026081210261859800_ref127","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1021\/acsmedchemlett.4c00395","article-title":"Discovery of PARP1-sparing inhibitors for protein ADP-ribosylation","volume":"15","author":"Stephens","year":"2024","journal-title":"ACS Med Chem Lett"},{"key":"2026081210261859800_ref128","doi-asserted-by":"publisher","first-page":"13843","DOI":"10.1039\/D3CC04343F","article-title":"A ribose-functionalized NAD(+) with versatile activity for ADP-ribosylation","volume":"59","author":"Stephens","year":"2023","journal-title":"Chem Commun (Camb)"},{"key":"2026081210261859800_ref129","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1152\/physrev.00035.2007","article-title":"Evolution and function of the ADP ribosyl cyclase\/CD38 gene family in physiology and pathology","volume":"88","author":"Malavasi","year":"2008","journal-title":"Physiol Rev"},{"key":"2026081210261859800_ref130","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1042\/BJ20071083","article-title":"The role of the diphthamide-containing loop within eukaryotic elongation factor 2 in ADP-ribosylation by Pseudomonas aeruginosa exotoxin A","volume":"413","author":"Zhang","year":"2008","journal-title":"Biochem J"},{"key":"2026081210261859800_ref131","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1039\/D1SC06256E","article-title":"Discovery of an NAD(+) analogue with enhanced specificity for PARP1","volume":"13","author":"Zhang","year":"2022","journal-title":"Chem Sci"},{"key":"2026081210261859800_ref132","doi-asserted-by":"publisher","first-page":"5267","DOI":"10.1021\/acs.biomac.2c01090","article-title":"A poly-ADP-ribose polymer-GCSF conjugate","volume":"23","author":"Cheng","year":"2022","journal-title":"Biomacromolecules"},{"key":"2026081210261859800_ref133","doi-asserted-by":"publisher","DOI":"10.1016\/j.tet.2024.134361","article-title":"An NAD(+) with dually modified adenine for labeling ADP-ribosylation-specific proteins","volume":"168","author":"Zhang","year":"2024","journal-title":"Tetrahedron"},{"key":"2026081210261859800_ref134","doi-asserted-by":"publisher","first-page":"27629","DOI":"10.1074\/jbc.M109.030965","article-title":"Mechanism of cyclizing NAD to cyclic ADP-ribose by ADP-ribosyl cyclase and CD38*\u2666","volume":"284","author":"Graeff","year":"2009","journal-title":"J Biol Chem"},{"key":"2026081210261859800_ref135","doi-asserted-by":"publisher","first-page":"13239","DOI":"10.1021\/bi981248s","article-title":"The reaction mechanism for CD38. A single intermediate is responsible for cyclization, hydrolysis, and base-exchange chemistries","volume":"37","author":"Sauve","year":"1998","journal-title":"Biochemistry"},{"key":"2026081210261859800_ref136","doi-asserted-by":"publisher","first-page":"9606","DOI":"10.1016\/S0021-9258(19)50133-8","article-title":"Slow-binding inhibition of NAD+ glycohydrolase by arabino analogues of beta-NAD","volume":"267","author":"Muller-Steffner","year":"1992","journal-title":"J Biol Chem"},{"key":"2026081210261859800_ref137","doi-asserted-by":"publisher","first-page":"7855","DOI":"10.1021\/ja001139c","article-title":"A covalent intermediate in CD38 is responsible for ADP-ribosylation and cyclization reactions","volume":"122","author":"Sauve","year":"2000","journal-title":"J Am Chem Soc"},{"key":"2026081210261859800_ref138","doi-asserted-by":"publisher","first-page":"8337","DOI":"10.1039\/C8SC03899F","article-title":"Facile chemoenzymatic synthesis of a novel stable mimic of NAD+","volume":"9","author":"Dai","year":"2018","journal-title":"Chem Sci"},{"key":"2026081210261859800_ref139","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1021\/jacs.5b12547","article-title":"Discovery of pyrophosphate diesters as tunable, soluble, and bioorthogonal linkers for site-specific antibody\u2013drug conjugates","volume":"138","author":"Kern","year":"2016","journal-title":"J Am Chem Soc"},{"key":"2026081210261859800_ref140","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.ymthe.2025.01.025","article-title":"Genetically reprogrammed exosomes for immunotherapy of acute myeloid leukemia","volume":"33","author":"Zhang","year":"2025","journal-title":"Mol Ther"},{"key":"2026081210261859800_ref141","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1021\/bc9000257","article-title":"Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-alkylguanine DNA alkyltransferase","volume":"20","author":"Kampmeier","year":"2009","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref142","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00432-015-1975-5","article-title":"Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities","volume":"141","author":"Niesen","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026081210261859800_ref143","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1021\/acs.bioconjchem.8b00545","article-title":"Simultaneous and independent dual site-specific self-labeling of recombinant antibodies","volume":"29","author":"Wollschlaeger","year":"2018","journal-title":"Bioconjug Chem"},{"key":"2026081210261859800_ref144","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1021\/jacs.5b00620","article-title":"An immunosuppressive antibody-drug conjugate","volume":"137","author":"Wang","year":"2015","journal-title":"J Am Chem Soc"},{"key":"2026081210261859800_ref145","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.835677","article-title":"The use of antibody-antibiotic conjugates to fight bacterial infections","volume":"13","author":"Cavaco","year":"2022","journal-title":"Front Microbiol"},{"key":"2026081210261859800_ref146","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.trecan.2023.01.003","article-title":"Antibody-drug conjugates: in search of partners of choice","volume":"9","author":"Fuentes-Antras","year":"2023","journal-title":"Trends Cancer"},{"key":"2026081210261859800_ref147","doi-asserted-by":"publisher","first-page":"8360","DOI":"10.1038\/s41598-017-08641-3","article-title":"Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system","volume":"7","author":"Han","year":"2017","journal-title":"Sci Rep"},{"key":"2026081210261859800_ref148","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1021\/acschembio.8b00222","article-title":"Generation of potent anti-HER1\/2 immunotoxins by protein ligation using split inteins","volume":"13","author":"Pirzer","year":"2018","journal-title":"ACS Chem Biol"}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbag020\/68185678\/tbag020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/3\/259\/68185678\/tbag020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/3\/259\/68185678\/tbag020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:27:34Z","timestamp":1786544854000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/9\/3\/259\/8664744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":148,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6,29]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbag020","relation":{},"ISSN":["2516-4236"],"issn-type":[{"value":"2516-4236","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,4,29]]}}}